Skip to main content

Urological oncology

This section considers clinical studies relevant to oncological disorders in urology

Page 6 of 6

  1. Malignant transformation describes the phenomenon in which a somatic component of a germ cell teratoma undergoes malignant differentiation. A variety of different types of sarcoma and carcinoma, all non-germ c...

    Authors: Nina Zeh, Peter J Wild, Peter K Bode, Glen Kristiansen, Holger Moch, Tullio Sulser and Thomas Hermanns

    Citation: BMC Urology 2013 13:9

    Content type: Case report

    Published on:

  2. We sought to improve prostate cancer (PC) detection through developing a prostate biopsy clinical decision rule (PBCDR), based on an elevated PSA and laboratory biomarkers. This decision rule could be used aft...

    Authors: Owen T Hill, Thomas J Mason, Skai W Schwartz and Philip R Foulis

    Citation: BMC Urology 2013 13:6

    Content type: Research article

    Published on:

  3. Urinary bladder carcinoma stage T1 is an unpredictable disease that in some cases has a good prognosis with only local or no recurrence, but in others can appear as a more aggressive tumor with progression to ...

    Authors: Hans Olsson, Per Hultman, Johan Rosell, Peter Söderkvist and Staffan Jahnson

    Citation: BMC Urology 2013 13:5

    Content type: Research article

    Published on:

  4. Prostate cancer is the second most commonly diagnosed cancer in American men over the age of 45 years and is the third most common cause of cancer related deaths in American men. In 2012 it is estimated that 2...

    Authors: Diego A Palacios, Makito Miyake and Charles J Rosser

    Citation: BMC Urology 2013 13:4

    Content type: Review

    Published on:

  5. Papillary renal cell carcinoma is a rare cancer. Some cases can be attributed to individuals with hereditary renal cell carcinomas usually consisting of the clear cell subtype. In addition, two syndromes with ...

    Authors: Carl Ludwig Behnes, Christina Schlegel, Moneef Shoukier, Isabella Magiera, Frank Henschke, Alexander Schwarz, Felix Bremmer and Hagen Loertzer

    Citation: BMC Urology 2013 13:3

    Content type: Case report

    Published on:

  6. To clarify the significant clinicopathological and postdosimetric parameters to predict PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.

    Authors: Nobumichi Tanaka, Isao Asakawa, Kiyohide Fujimoto, Satoshi Anai, Akihide Hirayama, Masatoshi Hasegawa, Noboru Konishi and Yoshihiko Hirao

    Citation: BMC Urology 2012 12:28

    Content type: Research article

    Published on:

  7. To assess the possibility of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP) as a biological marker for detecting Bladder cancer (BCa), we examined the expression of HIP/PAP in bot...

    Authors: Yujiro Nitta, Hiroyuki Konishi, Tetsuya Makino, Tomoaki Tanaka, Hidenori Kawashima, Juan L Iovanna, Tatsuya Nakatani and Hiroshi Kiyama

    Citation: BMC Urology 2012 12:24

    Content type: Research article

    Published on:

  8. Prevention of bladder cancer recurrence is a central challenge in the management of this highly prevalent disease. The histone deacetylase inhibitor valproic acid (sodium valproate) has anti-angiogenic propert...

    Authors: Timothy K Byler, Dean Leocadio, Oleg Shapiro, Gennady Bratslavsky, Christopher J Stodgell, Ronald W Wood, Edward M Messing and Jay E Reeder

    Citation: BMC Urology 2012 12:21

    Content type: Research article

    Published on:

  • BMC Urology works with with Cochrane Urology in providing our authors with expert advice on systematic reviews and meta-analyses

COVID-19 Announcement

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time. Thank you.

2018 Journal Metrics